Session
Pharmaceutical and Natural Sciences
Description
The newly identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV- 2) that originated in December 2019 in Wuhan, China. By July 2020, the WHO reported over 17 million confirmed cases in over 200 countries around the globe. This review discusses how the COVID-19 pandemic may affect healthy people, structure and replication cycle of SARS- CoV-2; targets and therapeutics SARS- CoV-2 and anti-COVID drugs: strategies and perspectives.
Keywords:
SARS-CoV-2, structure and replication, therapeutics drugs, multidrug combination, transmission of SARS-CoV-2
Session Chair
Shkëlzim Ukaj
Session Co-Chair
Hyzer Rizani
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-437-96-7
First Page
9
Last Page
24
Location
Lipjan, Kosovo
Start Date
31-10-2020 1:30 PM
End Date
31-10-2020 3:00 PM
DOI
10.33107/ubt-ic.2020.445
Recommended Citation
Temaj, Gazmend; Xharra, Kumrije Sopi; Xharra, Shefki; Moder, Angelika; Nurkovic, Jasmin; Hefic, Hilada; and Hadziselimovic, Rifat, "Investigational Anti SARS-COVID 19 Medication" (2020). UBT International Conference. 295.
https://knowledgecenter.ubt-uni.net/conference/2020/all_events/295
Included in
Investigational Anti SARS-COVID 19 Medication
Lipjan, Kosovo
The newly identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV- 2) that originated in December 2019 in Wuhan, China. By July 2020, the WHO reported over 17 million confirmed cases in over 200 countries around the globe. This review discusses how the COVID-19 pandemic may affect healthy people, structure and replication cycle of SARS- CoV-2; targets and therapeutics SARS- CoV-2 and anti-COVID drugs: strategies and perspectives.